Baoying Hu

1.1k total citations
30 papers, 766 citations indexed

About

Baoying Hu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Baoying Hu has authored 30 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Immunology. Recurrent topics in Baoying Hu's work include RNA modifications and cancer (7 papers), Ubiquitin and proteasome pathways (6 papers) and Cancer-related Molecular Pathways (5 papers). Baoying Hu is often cited by papers focused on RNA modifications and cancer (7 papers), Ubiquitin and proteasome pathways (6 papers) and Cancer-related Molecular Pathways (5 papers). Baoying Hu collaborates with scholars based in China and South Korea. Baoying Hu's co-authors include Chunhua Wan, Fengbo Zhao, Jiejie Xu, Han Zeng, Yu Zhu, Yuan Chang, Weijuan Zhang, Yangyang Qi, Bo Dai and Fei Qian and has published in prestigious journals such as Cancer Research, Biochemical and Biophysical Research Communications and European Urology.

In The Last Decade

Baoying Hu

30 papers receiving 762 citations

Peers

Baoying Hu
Noritaka Minagawa Japan
Peng Qu China
Weifan Weng United States
Peng Kuang China
Renuga Devi Rajaram Switzerland
Long Cui China
Minseob Eom South Korea
Xianghuai Lu United States
Noritaka Minagawa Japan
Baoying Hu
Citations per year, relative to Baoying Hu Baoying Hu (= 1×) peers Noritaka Minagawa

Countries citing papers authored by Baoying Hu

Since Specialization
Citations

This map shows the geographic impact of Baoying Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baoying Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baoying Hu more than expected).

Fields of papers citing papers by Baoying Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baoying Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baoying Hu. The network helps show where Baoying Hu may publish in the future.

Co-authorship network of co-authors of Baoying Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Baoying Hu. A scholar is included among the top collaborators of Baoying Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baoying Hu. Baoying Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Xingchao, et al.. (2022). High Expression of CSF-1R Predicts Poor Prognosis and CSF-1Rhigh Tumor-Associated Macrophages Inhibit Anti-Tumor Immunity in Colon Adenocarcinoma. Frontiers in Oncology. 12. 850767–850767. 14 indexed citations
3.
Chen, Gong, et al.. (2022). β2-adrenergic receptor drives the metastasis and invasion of pancreatic ductal adenocarcinoma through activating Cdc42 signaling pathway. Journal of Molecular Histology. 53(4). 645–655. 3 indexed citations
4.
Wang, Yi, et al.. (2021). Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 11. 666418–666418. 10 indexed citations
5.
Sun, Mengmeng, Han Zeng, Kaifeng Jin, et al.. (2021). Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. Cancer Immunology Immunotherapy. 71(6). 1497–1506. 25 indexed citations
6.
Fu, Qiang, Le Xu, Yiwei Wang, et al.. (2018). Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. European Urology. 75(5). 752–763. 164 indexed citations
7.
Qian, Fei, et al.. (2017). High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer. Human Pathology. 64. 61–68. 43 indexed citations
8.
Wang, Dongzhi, et al.. (2017). Low expression of NKD2 is associated with enhanced cell proliferation and poor prognosis in human hepatocellular carcinoma. Human Pathology. 72. 80–90. 9 indexed citations
9.
Zhang, Xiubing, Hua Lu, Fengbo Zhao, et al.. (2016). Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma. Oncology Reports. 36(6). 3456–3464. 36 indexed citations
10.
Cui, Xiaopeng, Zhipeng Lin, Yuyan Chen, et al.. (2016). Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma. Molecular and Cellular Biochemistry. 421(1-2). 127–137. 36 indexed citations
11.
Lin, Zhipeng, Baoying Hu, Wenkai Ni, et al.. (2016). Expression pattern of BCCIP in hepatocellular carcinoma is correlated with poor prognosis and enhanced cell proliferation. Tumor Biology. 37(12). 16305–16315. 6 indexed citations
12.
Lu, Hua, Baoying Hu, Jinxia Liu, et al.. (2016). Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Pathology - Research and Practice. 213(6). 688–697. 11 indexed citations
13.
Hu, Baoying, Hua Lu, Wenkai Ni, et al.. (2016). Nucleostemin/GNL3 promotes nucleolar polyubiquitylation of p27kip1 to drive hepatocellular carcinoma progression. Cancer Letters. 388. 220–229. 15 indexed citations
14.
Lv, Xiufang, Fengbo Zhao, Xisong Huo, et al.. (2016). Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma. Medical Oncology. 33(7). 70–70. 20 indexed citations
15.
Hu, Baoying, Yan Xia, Fang Liu, et al.. (2015). Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression. Pathology & Oncology Research. 22(3). 555–565. 13 indexed citations
16.
Hu, Baoying, Dawei Jiang, Yuyan Chen, et al.. (2015). High CHMP4B expression is associated with accelerated cell proliferation and resistance to doxorubicin in hepatocellular carcinoma. Tumor Biology. 36(4). 2569–2581. 19 indexed citations
17.
18.
19.
Jiang, Dawei, Baoying Hu, Gang Wang, et al.. (2014). High expression of vacuolar protein sorting 4B (VPS4B) is associated with accelerated cell proliferation and poor prognosis in human hepatocellular carcinoma. Pathology - Research and Practice. 211(3). 240–247. 15 indexed citations
20.
Hu, Baoying, Runzhou Ni, Dawei Jiang, et al.. (2014). The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Molecular and Cellular Biochemistry. 396(1-2). 175–185. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noritaka Minagawa Breakdown of academic impact, for papers by Peng Qu Breakdown of academic impact, for papers by Weifan Weng Breakdown of academic impact, for papers by Peng Kuang Breakdown of academic impact, for papers by Renuga Devi Rajaram Breakdown of academic impact, for papers by Long Cui Breakdown of academic impact, for papers by Minseob Eom Breakdown of academic impact, for papers by Xianghuai Lu
Rankless by CCL
2026